Lacrimal Gland Insufficiency in Aqueous Deficiency Dry Eye Disease: Recent Advances in Pathogenesis, Diagnosis, and Treatment

References

• Donthineni PR, Kammari P, Shanbhag SS, Singh V, Das AV, Basu S. Incidence, demographics, types and risk factors of dry eye disease in India: electronic medical records driven big data analytics report I. Ocul Surf. 2019;17(2):250–256. doi:10.1016/j.jtos.2019.02.007.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15(3):276–283. doi:10.1016/j.jtos.2017.05.008.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–812. doi:10.1016/j.jtos.2017.08.003.
   PubMed Web of Science ®Google Scholar
• Hessen M, Akpek EK. Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res. 2014;9:240–250.
   PubMedGoogle Scholar
• Brito-Zerón P, Ramos-Casals M. Advances in the understanding and treatment of systemic complications in Sjögren’s syndrome. Curr Opin Rheumatol. 2014;26(5):520–527. doi:10.1097/BOR.0000000000000096.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhou L, Liu B. Update on disease pathogenesis, diagnosis, and management of primary Sjögren’s syndrome. Int J Rheum Dis. 2020;23(6):723–727. doi:10.1111/1756-185X.13839.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis. 2002;61(6):554–558. doi:10.1136/ard.61.6.554.
   PubMed Web of Science ®Google Scholar
• Tian Y, Yang H, Liu N, Li Y, Chen J. Advances in pathogenesis of Sjögren’s syndrome. J Immunol Res. 2021;2021:5928232. doi:10.1155/2021/5928232.
   PubMed Web of Science ®Google Scholar
• Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375(24):2369–2379. doi:10.1056/NEJMra1600266.
   PubMed Web of Science ®Google Scholar
• Zhong D, Wu C, Zeng X, Wang Q. The role of gut microbiota in the pathogenesis of rheumatic diseases. Clin Rheumatol. 2018;37(1):25–34. doi:10.1007/s10067-017-3821-4.
   PubMed Web of Science ®Google Scholar
• de Paiva CS, Jones DB, Stern ME, et al. Altered mucosal microbiome diversity and disease severity in Sjögren syndrome. Sci Rep. 2016;6(1):23561. doi:10.1038/srep23561.
   PubMedGoogle Scholar
• Mandl T, Marsal J, Olsson P, Ohlsson B, Andréasson K. Severe intestinal dysbiosis is prevalent in primary Sjögren’s syndrome and is associated with systemic disease activity. Arthritis Res Ther. 2017;19(1):237. doi:10.1186/s13075-017-1446-2.
   PubMedGoogle Scholar
• Donthineni PR, Das AV, Basu S. Dry eye disease in children and adolescents in India. Ocul Surf. 2020 Oct;18(4):777–782. doi:10.1016/j.jtos.2020.07.019.
   PubMed Web of Science ®Google Scholar
• Adams J, Schaaf CP. Diagnosis and genetics of alacrima. Clin Genet. 2018;94(1):54–60. doi:10.1111/cge.13173.
   PubMed Web of Science ®Google Scholar
• Zhao Z, Allen RC. Congenital alacrima. Orbit. 2021;41(2):162–169. doi:10.1080/01676830.2021.1974057.
   PubMedGoogle Scholar
• Gupta N, Farooqui JH, Agni M, Kumar A, Sharma M, Mathur U. Alacrima, a rare cause of pediatric dry eye. J Aapos. 2018;22(3):233–235. doi:10.1016/j.jaapos.2017.11.003.
   PubMed Web of Science ®Google Scholar
• Fraunfelder FT, Sciubba JJ, Mathers WD. The role of medications in causing dry eye. J Ophthalmol. 2012;2012:285851. doi:10.1155/2012/285851.
   PubMed Web of Science ®Google Scholar
• Singh S. Congenital alacrimia with lacrimal gland hypoplasia. Orbit. 2021;1. doi:10.1080/01676830.2021.1942503.
   PubMedGoogle Scholar
• Bianchine JR, Macaraeg PV Jr., Lasagna L, et al. Drugs as etiologic factors in the Stevens-Johnson syndrome. Am J Med. 1968;44(3):390–405. doi:10.1016/0002-9343(68)90110-1.
   PubMed Web of Science ®Google Scholar
• Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79(3):389–398. doi:10.4103/0378-6323.110749.
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Viboud C, Dunant A, et al. Stevens- Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35–44. doi:10.1038/sj.jid.5701033.
   PubMed Web of Science ®Google Scholar
• McCormack JG. Mycoplasma pneumoniae and the erythema multiforme–Stevens Johnson syndrome. J Infect. 1981;3(1):32–36. doi:10.1016/S0163-4453(81)92236-2.
   PubMed Web of Science ®Google Scholar
• Schwartz RA, McDonough PH, Lee BW. Toxic epidermal necrolysis: part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. J Am Acad Dermatol. 2013;69(2):173.e1-13; quiz 85–6. doi:10.1016/j.jaad.2013.05.003.
   Web of Science ®Google Scholar
• Williams GP, Tomlins PJ, Denniston AK, et al. Elevation of conjunctival epithelial CD45INTCD11b⁺CD16⁺CD14⁻ neutrophils in ocular Stevens- Johnson syndrome and toxic epidermal necrolysis. Invest Ophthalmol Vis Sci. 2013;54(7):4578–4585. doi:10.1167/iovs.13-11859.
   PubMed Web of Science ®Google Scholar
• Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics. 2012;13(11):1285–1306. doi:10.2217/pgs.12.108.
   PubMed Web of Science ®Google Scholar
• Carreno-Galeano JT, Dohlman TH, Kim S, Yin J, Dana R. A review of ocular graft-versus-host disease: pathophysiology, clinical presentation and management. Ocul Immunol Inflammation. 2021;29(6):1190–1199. doi:10.1080/09273948.2021.1939390.
   PubMed Web of Science ®Google Scholar
• Tung CI. Current approaches to treatment of ocular graft-versus-host disease. Int Ophthalmol Clin. 2017;57(2):65–88. doi:10.1097/IIO.0000000000000167.
   PubMedGoogle Scholar
• Lorber M. Gross characteristics of normal human lacrimal glands. Ocul Surf. 2007;5(1):13–22. doi:10.1016/S1542-0124(12)70049-6.
   PubMed Web of Science ®Google Scholar
• Eugene WR. Wolff’s Anatomy of the Eye and Orbit. 7 ed. Philadelphia PA: WB Saunders; 1976. 222.
   Google Scholar
• Mafee MF, Haik BG. Lacrimal gland and fossa lesions: role of computed tomography. Radiol Clin North Am. 1987;25:767–779.
   PubMed Web of Science ®Google Scholar
• Forrester JVDA, McMenamin P, Lee WR. The Eye: Basic Sciences in Practice. 1. Philadelphia PA: WB Saunders; 1996.
   Google Scholar
• Snell RSLM. Clinical Anatomy of the Eye. 2. Malden MA: Blackwell Science; 1998.
   Google Scholar
• S T. Ocular Anatomy and physiology. Boston MA: Blackwell scientific; 1993.
   Google Scholar
• Forrester JVDA, McMenamin PG, Lee WR. The Eye. Basic Sciences in Practice. 2. Edinburgh: WB Saunders,; 2002.
   Google Scholar
• Singh S, Shanbhag SS, Basu S. Palpebral lobe of the human lacrimal gland: morphometric analysis in normal versus dry eyes. Br J Ophthalmol. 2021;105(10):1352–1357. doi:10.1136/bjophthalmol-2020-316929.
   PubMed Web of Science ®Google Scholar
• Jones LT. The lacrimal secretory system and its treatment. Am J Ophthalmol. 1966;62(1):47–60. doi:10.1016/0002-9394(66)91676-X.
   PubMed Web of Science ®Google Scholar
• Jordan A, Baum J. Basic tear flow Does it exist? Ophthalmol. 1980;87(9):920–930.doi:10.1016/S0161-6420(80)35143-9.
   PubMed Web of Science ®Google Scholar
• Singh S, Basu S. Effect of topical anesthesia on the secretory activity of the main lacrimal Gland. Cornea. 2020;39(10):e24–e5. doi:10.1097/ICO.0000000000002410.
   PubMed Web of Science ®Google Scholar
• Singh S, Basu S. The human lacrimal gland: historical perspectives, current understanding, and recent advances. Curr Eye Res. 2020;45(10):1188–1198. doi:10.1080/02713683.2020.1774065.
   PubMed Web of Science ®Google Scholar
• Kim EC, Doh SH, Chung SY, et al. Direct visualization of aqueous tear secretion from lacrimal gland. Acta Ophthalmol. 2017;95(4):e314–e22. doi:10.1111/aos.13335.
   PubMed Web of Science ®Google Scholar
• Bron AJ. Lacrimal streams: the demonstration of human lacrimal fluid secretion and the lacrimal ductules. Br J Ophthalmol. 1986;70(4):241–245. doi:10.1136/bjo.70.4.241.
   PubMed Web of Science ®Google Scholar
• Obata H. Anatomy and histopathology of the human lacrimal gland. Cornea. 2006;25(10 Suppl 1):S82–9. doi:10.1097/01.ico.0000247220.18295.d3.
   PubMed Web of Science ®Google Scholar
• Tóth-Molnár E, Ding C. New insight into lacrimal gland function: role of the duct epithelium in tear secretion. Ocul Surf. 2020;18(4):595–603. doi:10.1016/j.jtos.2020.07.002.
   PubMed Web of Science ®Google Scholar
• Singh S, Narang P, Vashist U, Mittal V. Histomorphological changes in lachrymal glands of patients with chronic Stevens-Johnson Syndrome. Cornea. 2019;38(9):e39–e40. doi:10.1097/ICO.0000000000002037.
   PubMed Web of Science ®Google Scholar
• Singh S, Mishra DK, Shanbhag S, et al. Lacrimal gland involvement in severe dry eyes after Stevens-Johnson Syndrome. Ophthalmology. 2021;128(4):621–624. doi:10.1016/j.ophtha.2020.08.016.
   PubMed Web of Science ®Google Scholar
• Singh S, Basu S. Ultrastructural study of the lacrimal glands in severe dry eye disease following Stevens-Johnson syndrome. Ocul Surf. 2022;23:204–206. doi:10.1016/j.jtos.2021.10.005.
   PubMed Web of Science ®Google Scholar
• Yokoi N, Georgiev GA, Kato H, et al. Classification of fluorescein breakup patterns: a Novel method of differential diagnosis for dry eye. Am J Ophthalmol. 2017;180:72–85. doi:10.1016/j.ajo.2017.05.022.
   PubMed Web of Science ®Google Scholar
• Yokoi N, Georgiev GA. Tear film–oriented diagnosis and tear film–oriented therapy for dry eye based on tear film dynamics. Invest Ophthalmol Vis Sci. 2018;59(14):DES13–DES22. doi:10.1167/iovs.17-23700.
   PubMed Web of Science ®Google Scholar
• Hong J, Sun X, Wei A, et al. Assessment of tear film stability in dry eye with a newly developed keratograph. Cornea. 2013;32(5):716–721. doi:10.1097/ICO.0b013e3182714425.
   PubMed Web of Science ®Google Scholar
• Fuller DG, Potts K, Kim J. Noninvasive tear breakup times and ocular surface disease. Optom Vis Sci. 2013;90(10):1086–1091. doi:10.1097/OPX.0000000000000023.
   PubMed Web of Science ®Google Scholar
• Lee R, Yeo S, Aung HT, Tong L. Agreement of noninvasive tear break-up time measurement between Tomey RT-7000 Auto refractor-keratometer and oculus keratograph 5M. Clin Ophthalmol. 2016;10:1785–1790. doi:10.2147/OPTH.S110180.
   PubMed Web of Science ®Google Scholar
• Cho P, Douthwaite W. The relation between invasive and noninvasive tear break-up time. Optom Vis Sci. 1995;72(1):17–22. doi:10.1097/00006324-199501000-00004.
   PubMed Web of Science ®Google Scholar
• Chan HH, Zhao Y, Tun TA, Tong L. Repeatability of tear meniscus evaluation using spectral- domain Cirrus® HD-OCT and time-domain Visante® OCT. Cont Lens Anterior Eye. 2015;38(5):368–372. doi:10.1016/j.clae.2015.04.002.
   PubMed Web of Science ®Google Scholar
• Qiu X, Gong L, Sun X, Jin H. Age-related variations of human tear meniscus and diagnosis of dry eye with Fourier-domain anterior segment optical coherence tomography. Cornea. 2011;30(5):543–549. doi:10.1097/ICO.0b013e3181fb84ea.
   PubMed Web of Science ®Google Scholar
• Fukuda R, Usui T, Miyai T, Yamagami S, Amano S. Tear meniscus evaluation by anterior segment swept-source optical coherence tomography. Am J Ophthalmol. 2013;155(4):620–4, 4.e1–2. doi:10.1016/j.ajo.2012.11.009.
   Web of Science ®Google Scholar
• Akiyama R, Usui T, Yamagami S. Diagnosis of dry eye by tear meniscus measurements using anterior segment swept source optical coherence tomography. Cornea. 2015;34(Supplement 11):S115–20. doi:10.1097/ICO.0000000000000583.
   PubMedGoogle Scholar
• Qiu X, Gong L, Lu Y, Jin H, Robitaille M. The diagnostic significance of Fourier-domain optical coherence tomography in Sjögren syndrome, aqueous tear deficiency and lipid tear deficiency patients. Acta Ophthalmol. 2012;90(5):e359–66. doi:10.1111/j.1755-3768.2012.02413.x.
   PubMed Web of Science ®Google Scholar
• Dogru M, Ishida K, Matsumoto Y, et al. Strip meniscometry: a new and simple method of tear meniscus evaluation. Invest Ophthalmol Vis Sci. 2006;47(5):901–1895. doi:10.1167/iovs.05-0802.
   PubMed Web of Science ®Google Scholar
• Ibrahim OM, Dogru M, Ward SK, et al. The efficacy, sensitivity, and specificity of strip meniscometry in conjunction with tear function tests in the assessment of tear meniscus. Invest Ophthalmol Vis Sci. 2011;52(5):2194–2198. doi:10.1167/iovs.10-5986.
   PubMed Web of Science ®Google Scholar
• Szalai E, Berta A, Szekanecz Z, Szûcs G, Módis L Jr. Evaluation of tear osmolarity in non- Sjögren and Sjögren syndrome dry eye patients with the TearLab system. Cornea. 2012;31(8):867–871. doi:10.1097/ICO.0b013e3182532047.
   PubMed Web of Science ®Google Scholar
• Versura P, Profazio V, Campos EC. Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases. Curr Eye Res. 2010;35(7):553–564. doi:10.3109/02713683.2010.484557.
   PubMed Web of Science ®Google Scholar
• Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol. 2011;151(5):792–8.e1. doi:10.1016/j.ajo.2010.10.032.
   PubMed Web of Science ®Google Scholar
• Thulasi P, Djalilian AR. Update in current diagnostics and therapeutics of dry eye disease. Ophthalmology. 2017;124(11s):S27–s33. doi:10.1016/j.ophtha.2017.07.022.
   PubMed Web of Science ®Google Scholar
• Lanza NL, McClellan AL, Batawi H, et al. Dry Eye Profiles in patients with a positive elevated surface matrix metalloproteinase 9 point-of-care test versus negative patients. Ocul Surf. 2016;14(2):216–223. doi:10.1016/j.jtos.2015.12.007.
   PubMed Web of Science ®Google Scholar
• Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix Metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay. Ophthalmology. 2016;123(11):2300–2308. doi:10.1016/j.ophtha.2016.07.028.
   PubMed Web of Science ®Google Scholar
• Sivak JM, Fini ME. MMPs in the eye: emerging roles for matrix metalloproteinases in ocular physiology. Prog Retin Eye Res. 2002;21(1):1–14. doi:10.1016/S1350-9462(01)00015-5.
   PubMed Web of Science ®Google Scholar
• Pinto-Fraga J, Enríquez-de-Salamanca A, Calonge M, et al. Severity, therapeutic, and activity tear biomarkers in dry eye disease: an analysis from a phase III clinical trial. Ocul Surf. 2018;16(3):368–376. doi:10.1016/j.jtos.2018.05.001.
   PubMed Web of Science ®Google Scholar
• Flanagan JL, Willcox MD. Role of lactoferrin in the tear film. Biochimie. 2009;91(1):35–43. doi:10.1016/j.biochi.2008.07.007.
   PubMed Web of Science ®Google Scholar
• Danjo Y, Lee M, Horimoto K, Hamano T. Ocular surface damage and tear lactoferrin in dry eye syndrome. Acta Ophthalmol (Copenh). 1994;72(4):433–437. doi:10.1111/j.1755-3768.1994.tb02791.x.
   PubMed Web of Science ®Google Scholar
• Sonobe H, Ogawa Y, Yamada K, et al. A novel and innovative paper-based analytical device for assessing tear lactoferrin of dry eye patients. Ocul Surf. 2019;17(1):160–166. doi:10.1016/j.jtos.2018.11.001.
   PubMed Web of Science ®Google Scholar
• Kojima T, Dogru M, Kawashima M, Nakamura S, Tsubota K. Advances in the diagnosis and treatment of dry eye. Prog Retin Eye Res. 2020;78:100842. doi:10.1016/j.preteyeres.2020.100842.
   Web of Science ®Google Scholar
• Matsumoto Y, Ibrahim OMA. Application of in vivo confocal microscopy in dry eye disease. Invest Ophthalmol Vis Sci. 2018;59(14):Des41–des7. doi:10.1167/iovs.17-23602.
   PubMed Web of Science ®Google Scholar
• Lemp MA. Management of dry eye disease. Am J Manag Care. 2008;14:S88–101.
   PubMed Web of Science ®Google Scholar
• Pucker AD, Ng SM, Nichols JJ. Over the counter (OTC) artificial tear drops for dry eye syndrome. Cochrane Database Syst Rev. 2016;2:Cd009729. doi:10.1002/14651858.CD009729.pub2.
   PubMed Web of Science ®Google Scholar
• Kamiya K, Nakanishi M, Ishii R, et al. Clinical evaluation of the additive effect of diquafosol tetrasodium on sodium hyaluronate monotherapy in patients with dry eye syndrome: a prospective, randomized, multicenter study. Eye (Lond). 2012;26(10):1363–1368. doi:10.1038/eye.2012.166.
   PubMed Web of Science ®Google Scholar
• Keating GM. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye. Drugs. 2015;75(8):911–922. doi:10.1007/s40265-015-0409-7.
   PubMed Web of Science ®Google Scholar
• Bremond-Gignac D, Gicquel JJ, Chiambaretta F. Pharmacokinetic evaluation of diquafosol tetrasodium for the treatment of Sjögren’s syndrome. Expert Opin Drug Metab Toxicol. 2014;10(6):905–913. doi:10.1517/17425255.2014.915026.
   PubMed Web of Science ®Google Scholar
• Nakamura M, Imanaka T, Sakamoto A. Diquafosol ophthalmic solution for dry eye treatment. Adv Ther. 2012;29(7):579–589. doi:10.1007/s12325-012-0033-9.
   PubMed Web of Science ®Google Scholar
• Takamura E, Tsubota K, Watanabe H, Ohashi Y. A randomised, double-masked comparison study of diquafosol versus sodium hyaluronate ophthalmic solutions in dry eye patients. Br J Ophthalmol. 2012;96(10):1310–1315. doi:10.1136/bjophthalmol-2011-301448.
   PubMed Web of Science ®Google Scholar
• Koh S, Ikeda C, Takai Y, Watanabe H, Maeda N, Nishida K. Long-term results of treatment with diquafosol ophthalmic solution for aqueous-deficient dry eye. Jpn J Ophthalmol. 2013;57(5):440–446. doi:10.1007/s10384-013-0251-y.
   PubMed Web of Science ®Google Scholar
• Carracedo G, Crooke A, Guzman-Aranguez A, de Lara Mj P, Martin-Gil A, Pintor J. The role of dinucleoside polyphosphates on the ocular surface and other eye structures. Prog Retin Eye Res. 2016;55:182–205. doi:10.1016/j.preteyeres.2016.07.001.
   PubMed Web of Science ®Google Scholar
• Fujihara T, Murakami T, Fujita H, Nakamura M, Nakata K. Improvement of corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96–100.
   PubMed Web of Science ®Google Scholar
• Kashima T, Itakura H, Akiyama H, Kishi S. Rebamipide ophthalmic suspension for the treatment of dry eye syndrome: a critical appraisal. Clin Ophthalmol (Auckland, NZ). 2014;8:1003–1010. doi:10.2147/OPTH.S40798.
   PubMedGoogle Scholar
• Kinoshita S, Awamura S, Oshiden K, Nakamichi N, Suzuki H, Yokoi N. Rebamipide (OPC- 12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study. Ophthalmology. 2012;119(12):2471–2478. doi:10.1016/j.ophtha.2012.06.052.
   PubMed Web of Science ®Google Scholar
• Tajima K, Hattori T, Takahashi H, et al. Rebamipide suppresses TNF-α production and macrophage infiltration in the conjunctiva. Vet Ophthalmol. 2018;21(4):347–352. doi:10.1111/vop.12510.
   PubMed Web of Science ®Google Scholar
• Itoh S, Itoh K, Shinohara H. Regulation of human corneal epithelial mucins by rebamipide. Curr Eye Res. 2014;39(2):133–141. doi:10.3109/02713683.2013.834939.
   PubMed Web of Science ®Google Scholar
• Fox RI. Use of cevimeline, a muscarinic M1 and M3 agonist, in the treatment of Sjögren’s syndrome. Adv Exp Med Biol. 2002;506:1107–1116.
   PubMed Web of Science ®Google Scholar
• Ono M, Takamura E, Shinozaki K, et al. Therapeutic effect of cevimeline on dry eye in patients with Sjögren’s syndrome: a randomized, double-blind clinical study. Am J Ophthalmol. 2004;138(1):6–17. doi:10.1016/j.ajo.2004.02.010.
   PubMed Web of Science ®Google Scholar
• Petrone D, Condemi JJ, Fife R, Gluck O, Cohen S, Dalgin P. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca. Arthritis Rheumatism. 2002;46(3):748–754. doi:10.1002/art.510.
   PubMed Web of Science ®Google Scholar
• Vivino FB, Al-Hashimi I, Khan Z, et al. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 study group. Arch int med. 1999;159(2):174–181. doi:10.1001/archinte.159.2.174.
   PubMedGoogle Scholar
• Periman LM, Perez VL, Saban DR, Lin MC, Neri P. The immunological basis of dry eye disease and current topical treatment options. J Ocul Pharmacol Ther. 2020;36(3):137–146. doi:10.1089/jop.2019.0060.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26(4):287–296. doi:10.5301/ejo.5000779.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000;107(4):631–639. doi:10.1016/S0161-6420(99)00176-1.
   PubMed Web of Science ®Google Scholar
• Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A Phase 2 study group. Ophthalmology. 2000;107(5):967–974. doi:10.1016/S0161-6420(00)00035-X.
   PubMed Web of Science ®Google Scholar
• Tuan HI, Chi SC, Kang YN. An updated systematic review with meta-analysis of randomized trials on topical cyclosporin A for dry-eye disease. Drug Des Devel Ther. 2020;14:265–274. doi:10.2147/DDDT.S207743.
   PubMed Web of Science ®Google Scholar
• Mandal A, Gote V, Pal D, Ogundele A, Mitra AK. Ocular pharmacokinetics of a topical ophthalmic nanomicellar solution of cyclosporine (Cequa®) for dry eye disease. Pharm Res. 2019;36(2):36. doi:10.1007/s11095-018-2556-5.
   PubMed Web of Science ®Google Scholar
• Abidi A, Shukla P, Ahmad A. Lifitegrast: a novel drug for treatment of dry eye disease. J Pharmacol Pharmacother. 2016;7(4):194–198.doi:10.4103/0976-500X.195920.
   PubMed Web of Science ®Google Scholar
• Hsueh PY, Ju Y, Vega A, Edman MC, MacKay JA, Hamm-Alvarez SF. A multivalent ICAM-1 binding nanoparticle which inhibits ICAM-1 and LFA-1 interaction represents a new tool for the investigation of autoimmune-mediated dry eye. Int J Mol Sci. 2020;21(8):2758. doi:10.3390/ijms21082758.
   PubMed Web of Science ®Google Scholar
• Stem ME, Gao J, Morgan GA, et al. The role of ICAM-1 as a signal protein for predisposition of ocular surface inflammation. Adv Exp Med Biol. 2002;506(Pt B):753–759.
   PubMedGoogle Scholar
• Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol (Auckland, NZ). 2016;10:1083–1094. doi:10.2147/OPTH.S110557.
   PubMed Web of Science ®Google Scholar
• Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of lifitegrast ophthalmic solution 5.0% in patients with dry eye disease: a 1-Year, multicenter, randomized, placebo-controlled study. Cornea. 2016;35(6):741–748. doi:10.1097/ICO.0000000000000803.
   PubMed Web of Science ®Google Scholar
• Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology. 2014;121(2):475–483. doi:10.1016/j.ophtha.2013.09.015.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim YS, Park SH. Metformin as a Treatment Strategy for Sjögren’s syndrome. Int J Mol Sci. 2021;22:(13).
   Web of Science ®Google Scholar
• Sheppard JD Jr., Singh R, McClellan AJ, et al. Long-term supplementation with n-6 and n-3 PUFAs improves moderate-to-severe keratoconjunctivitis sicca: a randomized double-blind clinical trial. Cornea. 2013;32(10):1297–1304. doi:10.1097/+ICO.0b013e318299549c.
   PubMed Web of Science ®Google Scholar
• Rogers NM, Kireta S, Coates PT. Curcumin induces maturation-arrested dendritic cells that expand regulatory T cells in vitro and in vivo. Clin Exp Immunol. 2010;162(3):460–473. doi:10.1111/j.1365-2249.2010.04232.x.
   PubMed Web of Science ®Google Scholar
• Basu S, Shanbhag SS, Gokani A, Kedar R, Bahuguna C, Sangwan VS. Chronic ocular sequelae of Stevens-Johnson syndrome in children: long-term impact of appropriate therapy on natural history of disease. Am J Ophthalmol. May 2018;189:17–28. doi:10.1016/j.ajo.2018.01.028.
   PubMed Web of Science ®Google Scholar
• Shanbhag SS, Shah S, Singh M, Bahuguna C, Donthineni PR, Basu S. Lid-related keratopathy in Stevens-Johnson syndrome: natural course and impact of therapeutic interventions in children and adults. Am J Ophthalmol. Nov 2020;219:357–365. doi:10.1016/j.ajo.2020.07.006.
   PubMed Web of Science ®Google Scholar
• Alipour F, Kheirkhah A, Jabarvand Behrouz M. Use of mini scleral contact lenses in moderate to severe dry eye. Cont Lens Anterior Eye. 2012;35(6):272–276. doi:10.1016/j.clae.2012.07.006.
   PubMed Web of Science ®Google Scholar
• La Porta Weber S, Becco de Souza R, Gomes J Á P, Hofling-Lima AL. The use of the esclera scleral contact lens in the treatment of moderate to severe dry eye disease. Am J Ophthalmol. 2016;163:167–73.e1. doi:10.1016/j.ajo.2015.11.034.
   PubMed Web of Science ®Google Scholar
• Bavinger JC, DeLoss K, Mian SI. Scleral lens use in dry eye syndrome. Curr Opin Ophthalmol. 2015;26(4):319–324. doi:10.1097/ICU.0000000000000171.
   PubMed Web of Science ®Google Scholar
• Na JH, Jung JH, Park JG, Song PH, Song CH. Therapeutic effects of acupuncture in typical dry eye: a systematic review and meta-analysis. Acta Ophthalmol. 2021;99(5):489–498. doi:10.1111/aos.14651.
   PubMed Web of Science ®Google Scholar
• Kim BH, Kim MH, Kang SH, Nam HJ. Optimizing acupuncture treatment for dry eye syndrome: a systematic review. BMC Complement Altern Med. 2018;18(1):145. doi:10.1186/s12906-018-2202-0.
   PubMedGoogle Scholar
• Yang L, Yang Z, Yu H, Song H. Acupuncture therapy is more effective than artificial tears for dry eye syndrome: evidence based on a meta-analysis. Evidence-based complementary and alternative medicine: eCAM. 2015;2015:143858.
   PubMed Web of Science ®Google Scholar
• Kossler AL, Brinton M, Patel ZM, Dalal R, Ta CN, Palanker D. Chronic electrical stimulation for tear secretion: lacrimal vs. anterior ethmoid nerve. Ocul Surf. 2019;17(4):822–827. doi:10.1016/j.jtos.2019.08.012.
   PubMed Web of Science ®Google Scholar
• Senchyna M, Ousler GW, Jerkins G, et al. Effect of TrueTear™ on dry eye symptoms during exposure to a controlled adverse environment. Invest Ophthalmol Vis Sci. 2018;59(9):918.
   Web of Science ®Google Scholar
• Geerling G, Raus P, Murube J. Minor salivary gland transplantation. Dev Ophthalmol. 2008;41:243–254.
   PubMedGoogle Scholar
• Su JZ, Wang Z, Liu XJ, Lv L, Yu GY. Use of saliva flow rate measurement in minor salivary glands autotransplantation for treatment of severe dry eye disease. Br J Ophthalmol. 2021;2020–317552. doi:10.1136/bjophthalmol-2020-317552.
   Web of Science ®Google Scholar
• Qin Y, Zhang Y, Liang Q, et al. Labial salivary gland transplantation for severe dry eye in a rhesus monkey model. Invest Ophthalmol Vis Sci. 2018;59(6):2478–2486. doi:10.1167/iovs.18-23966.
   PubMed Web of Science ®Google Scholar
• Wakamatsu TH, Sant’Anna A, Cristovam PC, Alves VAF, Wakamatsu A, Gomes JAP. Minor salivary gland transplantation for severe dry eyes. Cornea. 2017;36(Suppl 1):S26–s33. doi:10.1097/ICO.0000000000001358.
   PubMedGoogle Scholar
• Singh S, Basu S. A novel diagnostic technique of measuring labial minor salivary gland secretions using sodium fluorescein dye: implications for patients with dry eyes. Semin Ophthalmol. 2022 Jan 2;37(1):111–116. doi:10.1080/08820538.2021.1926518.
   PubMed Web of Science ®Google Scholar
• Singh S, Basu S. Preoperative labial mucosa evaluation as a deciding tool for minor salivary gland transplantation. Ophthalmic Plast Reconstr Surg. 2021;37(3s):S121–s2. doi:10.1097/IOP.0000000000001842.
   PubMed Web of Science ®Google Scholar
• Singh S, Basu S. Functional assessment of transplanted minor salivary glands. Cornea. 2020;39(8):e21–e2. doi:10.1097/ICO.0000000000002359.
   PubMed Web of Science ®Google Scholar
• Marinho DR, Burmann TG, Kwitko S. Labial salivary gland transplantation for severe dry eye due to chemical burns and Stevens-Johnson syndrome. Ophthalmic Plast Reconstr Surg. 2010;26(3):182–184. doi:10.1097/IOP.0b013e3181b8c3ad.
   PubMed Web of Science ®Google Scholar
• Vazirani J, Bhalekar S, Amescua G, Singh S, Basu S. Minor salivary gland transplantation for severe dry eye disease due to cicatrising conjunctivitis: multicentre long-term outcomes of a modified technique. Br J Ophthalmol. 2020;105(11):1485–1490. doi:10.1136/bjophthalmol-2020-316611.
   PubMed Web of Science ®Google Scholar
• Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007;110(10):3499–3506. doi:10.1182/blood-2007-02-069716.
   PubMed Web of Science ®Google Scholar
• Weng J, He C, Lai P, et al. Mesenchymal stromal cells treatment attenuates dry eye in patients with chronic graft-versus-host disease. Mol Ther: J Am Soci Gene Ther. 2012;20(12):2347–2354. doi:10.1038/mt.2012.208.
   PubMed Web of Science ®Google Scholar
• Møller-Hansen M, Larsen AC, Toft PB, et al. Safety and feasibility of mesenchymal stem cell therapy in patients with aqueous deficient dry eye disease. Ocul Surf. 2021;19:43–52. doi:10.1016/j.jtos.2020.11.013.
   PubMed Web of Science ®Google Scholar
• Dietrich J, Schrader S. Towards lacrimal gland regeneration: current concepts and experimental approaches. Curr Eye Res. 2020;45(3):230–240. doi:10.1080/02713683.2019.1637438.
   PubMed Web of Science ®Google Scholar
• Kawakita T. Regeneration of lacrimal gland function to maintain the health of the ocular surface. Invest Ophthalmol Vis Sci. 2018;59(14):Des169–des73. doi:10.1167/iovs.17-23576.
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhang Y. The lacrimal gland: development, wound repair and regeneration. Biotechnol Lett. 2017;39(7):939–949. doi:10.1007/s10529-017-2326-1.
   PubMed Web of Science ®Google Scholar
• Liu CY, Hirayama M, Ali M, Shah D, Aakalu VK. Strategies for Regenerating the Lacrimal Gland. Current Ophthalmol Rep. 2017;5(3):193–198.doi:10.1007/s40135-017-0142-3.
   PubMedGoogle Scholar
• Hirayama M, Tsubota K, Tsuji T. Bioengineered Lacrimal Gland Organ Regeneration in Vivo. J Funct Biomater. 2015;6(3):634–649. doi:10.3390/jfb6030634.
   PubMedGoogle Scholar
• Hirayama M, Tsubota K, Tsuji T. Generation of a bioengineered lacrimal gland by using the organ germ method. Methods Mol Biol. 2017;1597:153–165.
   PubMedGoogle Scholar
• Bannier-Hélaouët M, Post Y, Korving J, et al. Exploring the human lacrimal gland using organoids and single-cell sequencing. Cell Stem Cell. 2021 Jul 1;28(7):1221–1232.e7. doi:10.1016/j.stem.2021.02.024.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, de Paiva CS. The pathophysiology of dry eye disease: what we know and future directions for research. Ophthalmology. 2017;124(11s):S4–s13. doi:10.1016/j.ophtha.2017.07.010.
   PubMed Web of Science ®Google Scholar
• Trujillo-Vargas CM, Schaefer L, Alam J, Pflugfelder SC, Britton RA, de Paiva CS. The gut-eye- lacrimal gland-microbiome axis in Sjögren Syndrome. Ocul Surf. 2020;18(2):335–344. doi:10.1016/j.jtos.2019.10.006.
   PubMed Web of Science ®Google Scholar
• Watane A, Cavuoto KM, Rojas M, et al. Fecal microbial transplant in individuals with immune-mediated dry eye. Am J Ophthalmol. 2022;233:90–100. doi:10.1016/j.ajo.2021.06.022.
   PubMed Web of Science ®Google Scholar